Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal versus intravenous remifentanil for hemodynamic control during general anesthesia induction and tracheal intubation
IRCT20101211005362N24Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Mar 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, triple-blind trial of remifentanil (3 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Hemodynamic changes including blood pressure and heart rate, Laryngoscopic duration and 3 more. Started Mar 2018; status: completed.
02
Drugs
remifentanil
Beyond the preview
Go deeper on IRCT20101211005362N24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20101211005362N24.